Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis

Ibrexafungerp (formerly SCY-078) is a semisynthetic triterpenoid and potent (1→3)-β-d-glucan synthase inhibitor. We investigated the in vitro activity, pharmacokinetics, and in vivo efficacy of ibrexafungerp (SCY) alone and in combination with antimold triazole isavuconazole (ISA) against invasive p...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Antimicrob Agents Chemother
Huvudupphovsmän: Petraitis, Vidmantas, Petraitiene, Ruta, Katragkou, Aspasia, Maung, Bo Bo Win, Naing, Ethan, Kavaliauskas, Povilas, Barat, Stephen, Borroto-Esoda, Katyna, Azie, Nkechi, Angulo, David, Walsh, Thomas J.
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society for Microbiology 2020
Ämnen:
Experimental Therapeutics
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7269506/
https://ncbi.nlm.nih.gov/pubmed/32179521
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02429-19
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk